559 related articles for article (PubMed ID: 34868078)
1. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review.
Qi F; Liu F; Gao L
Front Immunol; 2021; 12():790125. PubMed ID: 34868078
[TBL] [Abstract][Full Text] [Related]
2. The Use of Janus Kinase Inhibitors in Vitiligo: A Review of the Literature.
Relke N; Gooderham M
J Cutan Med Surg; 2019; 23(3):298-306. PubMed ID: 30902022
[TBL] [Abstract][Full Text] [Related]
3. Janus Kinase Inhibitors: A Review of Their Application in the Vitiligo.
Niu C; Xie H; Aisa HA
Mini Rev Med Chem; 2021; 21(20):3203-3218. PubMed ID: 33823765
[TBL] [Abstract][Full Text] [Related]
4. Pathogenic Th2 Cytokine Profile Skewing by IFN-γ-Responding Vitiligo Fibroblasts via CCL2/CCL8.
Jin R; Zhou M; Lin F; Xu W; Xu A
Cells; 2023 Jan; 12(2):. PubMed ID: 36672151
[TBL] [Abstract][Full Text] [Related]
5. JAK inhibitors for the treatment of vitiligo.
Inoue S; Suzuki T; Sano S; Katayama I
J Dermatol Sci; 2024 Mar; 113(3):86-92. PubMed ID: 38326166
[TBL] [Abstract][Full Text] [Related]
6. JAK-STAT pathway inhibitors in dermatology.
Miot HA; Criado PR; de Castro CCS; Ianhez M; Talhari C; Ramos PM
An Bras Dermatol; 2023; 98(5):656-677. PubMed ID: 37230920
[TBL] [Abstract][Full Text] [Related]
7. JAK inhibitors in vitiligo: what they hit and what they miss - an immunopathogenesis based exposition of existing evidence.
Sardana K; Muddebihal A; Khurana A
Expert Rev Clin Pharmacol; 2023; 16(12):1221-1227. PubMed ID: 37982238
[TBL] [Abstract][Full Text] [Related]
8. JAK-STAT signaling pathway inhibition: a role for treatment of various dermatologic diseases.
Kahn J; Deverapalli SC; Rosmarin D
Semin Cutan Med Surg; 2018 Sep; 37(3):198-208. PubMed ID: 30215638
[TBL] [Abstract][Full Text] [Related]
9. Role of JAK-STAT signaling in the pathogenic behavior of fibroblast-like synoviocytes in rheumatoid arthritis: Effect of the novel JAK inhibitor peficitinib.
Emori T; Kasahara M; Sugahara S; Hashimoto M; Ito H; Narumiya S; Higashi Y; Fujii Y
Eur J Pharmacol; 2020 Sep; 882():173238. PubMed ID: 32561292
[TBL] [Abstract][Full Text] [Related]
10. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A
J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126
[TBL] [Abstract][Full Text] [Related]
11. JAK Inhibitors Suppress Innate Epigenetic Reprogramming: a Promise for Patients with Sjögren's Syndrome.
Charras A; Arvaniti P; Le Dantec C; Arleevskaya MI; Zachou K; Dalekos GN; Bordon A; Renaudineau Y
Clin Rev Allergy Immunol; 2020 Apr; 58(2):182-193. PubMed ID: 31165348
[TBL] [Abstract][Full Text] [Related]
12. JAK-inhibitors in dermatology: current evidence and future applications.
Ciechanowicz P; Rakowska A; Sikora M; Rudnicka L
J Dermatolog Treat; 2019 Nov; 30(7):648-658. PubMed ID: 30433838
[TBL] [Abstract][Full Text] [Related]
13. Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions.
Ryguła I; Pikiewicz W; Kaminiów K
Molecules; 2023 Dec; 28(24):. PubMed ID: 38138551
[TBL] [Abstract][Full Text] [Related]
14. Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease.
Huang MY; Armstrong AW
Indian J Dermatol Venereol Leprol; 2023 [SEASON]; 90(1):30-40. PubMed ID: 38031699
[TBL] [Abstract][Full Text] [Related]
15. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
16. JAK Inhibitors: Prospects in Connective Tissue Diseases.
You H; Xu D; Zhao J; Li J; Wang Q; Tian X; Li M; Zeng X
Clin Rev Allergy Immunol; 2020 Dec; 59(3):334-351. PubMed ID: 32222877
[TBL] [Abstract][Full Text] [Related]
17. JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review.
Muddebihal A; Khurana A; Sardana K
Expert Rev Clin Pharmacol; 2023 Apr; 16(4):279-295. PubMed ID: 36946306
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
Howell MD; Kuo FI; Smith PA
Front Immunol; 2019; 10():2342. PubMed ID: 31649667
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological inhibition of demethylzeylasteral on JAK-STAT signaling ameliorates vitiligo.
Chang Y; Kang P; Cui T; Guo W; Zhang W; Du P; Yi X; Guo S; Gao T; Li C; Li S
J Transl Med; 2023 Jul; 21(1):434. PubMed ID: 37403086
[TBL] [Abstract][Full Text] [Related]
20. An overview of JAK/STAT pathways and JAK inhibition in alopecia areata.
Lensing M; Jabbari A
Front Immunol; 2022; 13():955035. PubMed ID: 36110853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
